Marie-Françoise D.
- Country
- Belgium
- Department
- Hémato - oncologie pédiatrique
Research Overview
- International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Evaluation of Dexamethasone Versus Prednisone in Induction Therapy for Pediatric and Adolescent Lymphoblastic Lymphoma: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 192 of 272 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of acute lymphoblastic leukemia (ALL), with particular emphasis on Philadelphia chromosome-positive ALL and relapsed cases. Their research extends to acute myeloid leukemia (AML) in pediatric and adolescent populations.
- Pediatric ALL Treatment Protocols
- AML Management Strategies
- Stem Cell Transplantation Approaches
Their work includes innovative conditioning regimens for transplantation and novel therapeutic combinations for resistant disease.
Lymphoma Studies
The investigator focuses on advanced treatments for ALK-positive anaplastic large cell lymphoma and lymphoblastic lymphoma in children and adolescents. Their research explores targeted therapeutic approaches including vinblastine monotherapy for standard-risk patients.
- ALCL Treatment Optimization
- Lymphoblastic Lymphoma Protocols
- Risk-Stratified Approaches
Their expertise includes developing treatment protocols that balance efficacy with reduced toxicity.
Hepatic Oncology
The investigator specializes in pediatric liver cancers, particularly hepatoblastoma and hepatocellular carcinoma. Their work encompasses various risk groups and treatment strategies, including novel therapeutic combinations for unresectable disease.
- Risk-Adapted Treatment Protocols
- Surgical Integration Strategies
- Novel Drug Combinations
Their research includes evaluating targeted therapies and optimizing treatment duration based on response.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.